Back to Stocks

CLDX

Celldex Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Celldex Therapeutics is aggressively transitioning from a clinical-stage entity to a near-commercial biopharmaceutical company.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline liquidity, Celldex faces a widening fiscal gap characterized by an operating loss of $84.4 million in the first quarter of 2026, a 35% increase over the prior year.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CLDX filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical juncture, balancing massive capital inflows against accelerating operational losses. The April public offering has provided a necessary runway, but the underlying financial trend shows a business that is becoming increasingly expensive to run as it nears the finish line. The trade-off for investors is now a matter of timing and clinical confidence. The overall impact of the filing is a shift in the risk profile from 'funding risk' to 'execution risk.' While the balance sheet is no longer the primary concern, the concentration of value in the barzolvolimab program creates a high-stakes environment. The market will likely remain volatile until the Q4 2026 topline data provides clarity on whether the company's capital-intensive bet on mast cell depletion will yield a commercial success.

Selected Quarter

Core Takeaway

Celldex has solved its immediate funding crisis with a $324M offering, shifting investor focus entirely to the Q4 2026 Phase 3 data readout.

Investor Lens

The trade-off is between the security of the current cash position and the binary risk of the upcoming Phase 3 data.

Watch Next

Topline data for the EMBARQ-CSU Phase 3 studies expected in Q4 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.10Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%
bullishMay 7

Secured $323.9 million in net proceeds from an April 2026 public offering.

capital raise
90%
bearishMay 7

Operating loss increased 35% year-over-year to $84.4 million.

margin compression
70%
bearishMay 7

Contract and grants revenue declined 98% year-over-year.

earnings miss
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical juncture, balancing massive capital inflows against accelerating operational losses. The April public offering has provided a necessary runway, but the underlying financial trend shows a business that is becoming increasingly expensive to run as it nears the finish line. The trade-off for investors is now a matter of timing and clinical confidence. The overall impact of the filing is a shift in the risk profile from 'funding risk' to 'execution risk.' While the balance sheet is no longer the primary concern, the concentration of value in the barzolvolimab program creates a high-stakes environment. The market will likely remain volatile until the Q4 2026 topline data provides clarity on whether the company's capital-intensive bet on mast cell depletion will yield a commercial success.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.